Journal
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
Volume 40, Issue 13, Pages 677-690Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/10826076.2017.1343735
Keywords
Brain pharmacokinetics; CS-PLGA nanoparticles; LC-MS/MS method validation; Parkinson's disease; rasagiline
Ask authors/readers for more resources
The aim of this study was to investigate the brain targeting potential of rasagiline-encapsulated chitosan-coated PLGA nanoparticles (RSG-CS-PLGA-NPs) delivered intranasally into the brain. Chitosan-coated PLGA nanoparticles (RSG-CS-PLGA-NPs) were developed through double emulsification-solvent evaporation technique. RSG-CS-PLGA-NPs were characterized for particle size, zeta potential, size distribution, encapsulation efficiency, and in vitro drug release. The mean particle size, polydispersity index, and encapsulation efficiency were found to be 122.38 +/- 3.64, 0.212 +/- 0.009, and 75.83 +/- 3.76, respectively. High-performance liquid chromatography-mass spectroscopy and mass spectroscopy study showed a significantly high mucoadhesive potential of RSG-CS-PLGA-NPs and least for conventional and homogenized nanoformulation. Pharmacokinetic results of RSG-CS-PLGA-NPs in Wistar rat brain and plasma showed a significantly high (**p<0.005) AUC(0-24) and amplified C-max over intravenous treatment group. Finally, the investigation demonstrated that intranasal delivery of mucoadhesive nanocarrier showed significant enhancement of bioavailability in brain, after administration of the RSG-CS-PLGA-NPs which could be a substantial achievement of direct nose to brain targeting in Parkinson's disease therapy and related brain disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available